Printer Friendly

CENTOCOR ANNOUNCES REORGANIZATION

 CENTOCOR ANNOUNCES REORGANIZATION
 MALVERN, Pa., April 28 /PRNewswire/ -- Centocor, Inc. (NASDAQ: CNTO)


today announced that its board of directors today created an executive committee chaired by Michael A. Wall.
 Wall, a founder of Centocor and a member of the board, was Centocor's chairman from 1979 to 1986. In his new position, he will work closely with Hubert J.P. Schoemaker, the chairman and chief executive officer of Centocor, in redefining the corporate strategy.
 As a result of shifting some of Centocor's fundamental goals, James E. Wavle Jr. has resigned as president and chief executive officer of Centocor. Wall said, "Jim Wavle's contributions to Centocor over the preceding five years to build a fully integrated pharmaceutical company cannot be overstated. He has brought unparalleled commitment and management talent to Centocor. Speaking for the entire board, I express regret at Jim's decision and wish him well."
 David P. Holveck, presently a Centocor executive vice president and president of the Diagnostics Division, was named president and chief operating officer of Centocor. Since his arrival at Centocor in 1983, Holveck has built the company's diagnostics business from a research- oriented activity into a profitable international enterprise. In his new position, he will have broad operating responsibilities throughout the company, including oversight of the marketing of both Centocor's therapeutic and diagnostic products. Holveck previously worked in the medical businesses of General Electric Co., Corning Glass Works, and Abbott Laboratories.
 "I look forward to working more closely with both Michael Wall and Dave Holveck as Centocor moves to overcome the challenges that confront our company. Following this reorganization, Centocor said it intends to aggressively pursue several objectives, including the raising of additional capital and the reduction of the company's cash-burn rate through both increased sales and a critical examination of expenses," Schoemaker said.
 Centocor, based in Malvern, develops, manufactures, and markets diagnostic and pharmaceutical products for human health care. The company's products are based on monoclonal antibody technology and are primarily intended for use in the management of patients with infectious, cardiovascular, and autoimmune diseases and cancer.
 /delval/
 -0- 4/28/92
 /CONTACT: Richard Koenig of Centocor, 215-651-6122/
 (CNTO) CO: Centocor, Inc. ST: Pennsylvania IN: MTC SU: RCN


CC -- PH027 -- 3876 04/28/92 13:52 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1992
Words:371
Previous Article:LOCKHEED BOARD BOOSTS DIVIDEND TO 53 CENTS PER QUARTER
Next Article:CLINICAL HOMECARE ANNOUNCES FIRST QUARTER 1992 RESULTS


Related Articles
TOCOR II, INC. AND CENTOCOR, INC. INCREASE SIZE OF UNIT OFFERING
CENTOCOR, INC. AND TOCOR II, INC. ANNOUNCE PUBLIC OFFERING OF 2,250,000 UNITS
CENTOCOR ACQUIRES MERCIA DIAGNOSTICS
CENTOCOR REPORTS RESULTS
CENTOCOR EXERCISES CPII PURCHASE OPTION
CENTOCOR REPORTS STATUS OF HA-1A(TM) LICENSE APPLICATION AT FDA
CENTOCOR REPORTS RESULTS OF OPERATIONS FOR THE QUARTER ENDED MARCH 31, 1992
XOMA AND CENTOCOR ANNOUNCE SETTLEMENT OF ALL OUTSTANDING LITIGATION AND DISPUTES
CENTOCOR TO EXTEND TOCOR II OFFER
Centocor to Settle Litigation

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters